Skip to main content
Premium Trial:

Request an Annual Quote

Cigna to Cover Interpace ThyGenX Thyroid MDx

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX molecular thyroid test will now be covered by Cigna.

The test uses next-generation sequencing to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, and is designed to assess fine needle aspiration samples from indeterminate thyroid nodules.

According to Interpace, ThyGenX will now be covered for Cigna's roughly 15 million members nationwide, effective immediately. The test is already covered by Aetna, UnitedHealthcare, Medicare, and other payors, bringing the total number of covered lives in the US to about 275 million, the company added.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.